Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Moderna Inc. said late Tuesday it has hammered out an agreement with Thermo Fisher Scientific for the manufacturing, labeling and packing of Moderna's COVID-19 vaccine at a Thermo Fisher plant in North Carolina. The agreement aims "to leverage manufacturing capacity to continue to drive global supply of vaccines," the company said.

Moderna, Thermo Fisher ink deal to make COVID-19 vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement with Thermo Fisher Scientific for fill/finish Manufacturing of Moderna's COVID-19 vaccine.

Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna's COVID-19 Vaccine

This instrument by Thermo Fisher (TMO) is set to play a vital role in developing advanced solar cells, transport alloys, battery materials, low-energy electronics, catalysts and biodegradable polymers.

Thermo Fisher's (TMO) New Alliance Boosts Electron Microscopy

Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.

Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal

WALTHAM, Mass. and SAN FRANCISCO, May 19, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of California, San Francisco (UCSF) today announced they have formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies.

Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center

Alphabet

Ecolab

Microsoft

The 20 largest ESG funds like tech. Google's parent company was the most commonly held stock across a majority of them.

Alphabet was the most widely held stock for the largest ESG funds. Here's what else they own

WALTHAM, Mass., May 10, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N.

Thermo Fisher Scientific to Present at the BofA Securities 2021 Healthcare Conference on May 12, 2021

With earnings growth averaging 16.2% per year over the past decade, Thermo Fisher Scientific Inc ( TMO , Financial) keeps its foot on the accelerator:

Thermo Fisher Scientific: Growth at a Reasonable Price

Abbott Labs

Hologic

Investors should hold off permanently rebranding diagnostics stocks as coronavirus stocks, experts say. There's a chance their future could be much brighter despite spreading vaccine use.

Why Vaccines Might Not Spell Downturn For Covid Testing Firms

Berkeley Lights, Inc.

Lockheed Martin

Virgin Galactic

Spotify

TuSimple Holdings

Unity Software

After a steep selloff in emerging growth companies, opportunities abound. Here are seven Cathie Wood stocks worth considering right now.

7 Cathie Wood Stocks That Are Worth Buying Now

Thermo Fisher Scientific is a good-quality stock that is well-positioned to grow via M&A and organically in a growing industry. We outline the recent PPD, Inc. acquisition.

Thermo Fisher Scientific Stock: A Bit Pricey But Can Still Perform Well Over The Long Run

Thermo Fisher Scientific Inc. (TMO) CEO Marc Casper on Q1 2021 Results - Earnings Call Transcript

Shares of Thermo Fisher Scientific (NYSE:TMO) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 145.24% over the past year to $7.21, which beat the estimate of $6.65.

Recap: Thermo Fisher Scientific Q1 Earnings

Calyxt

Zymergen

Here's what to look for and what to steer clear of.

2 Risky Life-Sciences Stocks to Avoid and 1 to Buy Now

WALTHAM, Mass., April 29, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021.

Thermo Fisher Scientific Reports First Quarter 2021 Results

CSL Ltd

Humana

M3 Inc

UnitedHealth Group

Investors may be interested in the following health care companies, as they have expanded their revenue per share and Ebitda per share by more than 10% over the trailing five-year and 10-year periods through April 28.

5 Health Care Stocks Growing Fast

Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.

Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PPD, Inc. (NasdaqGS: PPD) to Thermo Fisher Scientific Inc. (NYSE: TMO). Under the terms of the proposed transaction, shareholders of PPD will receive only $47.50 in cash for each share of PPD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w

PPD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PPD, Inc. - PPD

Thermo Fisher's (TMO) $17.4-billion acquisition deal will offer the company meaningful cost and revenue synergies.

Thermo Fisher (TMO) to Expand in Pharma Service With PPD Buyout

Align Technology

ICON

PRA Health Sciences

STERIS

Teladoc

DENTSPLY SIRONA

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

Thermo Fisher Scientific (TMO) has agreed to buy the healthcare testing company PPD Inc. (PPD) for $17.4 billion in cash.

5 ETFs to Make the Most of Thermo Fisher Deal to Buy PPD

The scientific company is acquiring PPD, a contract research organization that also provides lab services.

Thermo Fisher Bets Big on Clinical Research With a $17.4 Billion Deal

Thermo Fisher Scientific Inc. (NYSE: TMO) and PPD, Inc. (Nasdaq: PPD) announced their board of directors approved an agreement under which Thermo Fisher will acquire PPD for a total cash purchase of $17.4 billion. These are the details.

Thermo Fisher Scientific (TMO) Buying PPD In $17.4 Billion Deal

Thermo Fisher Scientific is buying clinical research organization PPD in a $17.4 billion cash-and-debt deal, the companies said Thursday. Both TMO stock and PPD stock popped on the news.

News for Thermo Fisher Scientific Stock (TMO)